In this Q&A, Carly Stafford Dixon discusses her lymphoma journey, recovery with CAR T therapy, and mission to raise support ...

Each one has a different treatment and outcome. Primary mediastinal B-cell lymphoma starts in a part of your chest called the mediastinum. It grows quickly, but it responds well to treatment.

Yescarta (axicabtagene ciloleucel) has been approved as a treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma ...

Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or ...

The approved indications for Yescarta are adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more ...

Primary Mediastinal Large B-Cell Lymphoma KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have ...

Furthermore, extended LB analysis of serum TARC levels, ctDNA variants, and CNAs revealed a subgroup of patients initially diagnosed as diffuse LBCL with a primary mediastinal B-cell lymphoma-like ...

A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas ...

Patients with primary cutaneous B-cell lymphoma showed a higher risk of developing prostate and hematologic cancers in a ...